CHANTILLY, Va.--(BUSINESS WIRE)--Notal Vision, Inc. is pleased to announce that the ForeseeHome AMD Monitoring Program is now available for eligible Medicare patients across the U.S. ForeseeHome is available by prescription for patients with Dry Age-related Macular Degeneration (AMD) at high risk for developing Wet AMD.
The clinical utility for ForeseeHome was established in the Home Monitoring of the Eye (HOME) Study, part of a National Eye Institute-sponsored study, where over 1500 patients were enrolled across 44 centers. The study was designed to evaluate whether ForeseeHome resulted in earlier detection of wet AMD compared to standard of care. 94% of patients using ForeseeHome who progressed to wet AMD maintained 20/40 or better vision, the cutoff for driving vision, compared to only 62% in the standard of care arm. In comparison, only 13-36% of wet AMD diagnosed in community-based studies and other key studies. The level of early wet AMD detection achieved by ForeseeHome, significantly increases the proportion of individuals diagnosed with functional vision. Early detection significantly increases the physician’s ability to preserve the patient’s vision.
“Notal Vision is extremely pleased to achieve this significant milestone with the ForeseeHome AMD Monitoring System. We have worked diligently for almost two years with the goal of ensuring this device is available to eligible patients enrolled in Medicare. Ultimately what this achieves is greater access to a first-of-its kind telemonitoring technology in Ophthalmology that helps AMD patients preserve their vision,” said Dr. Barak Azmon, CEO of Notal Vision.
Notal Vision is committed to providing support to eyecare physicians and their patients with the ForeseeHome AMD Monitoring Program. Information on prescribing ForeseeHome can be found at www.foreseehome.com or by contacting Notal Vision at 1-888-910-2020.
About Age-Related Macular Degeneration (AMD)
Age-related macular degeneration (AMD) is the leading cause of severe vision loss and blindness in adults over age 50. The early stage of the disease, known as dry AMD, causes damage to the part of the retina called the macula, which is responsible for detailed central vision tasks like reading, driving and facial recognition. Patients with dry AMD may progress to the wet form of AMD, in which blood vessels form and may leak fluid and blood onto the retina. Several studies indicate that early detection of warning signs of disease progression provides patients the best chance to start therapy and maintain good vision and a better quality of life.
About ForeseeHome Monitoring
ForeseeHome Monitoring uses a technology known as preferential hyperacuity perimetry (PHP) to detect pattern defects in 500 points in the central 14° of a patient’s retina. Over 1 million tests have been performed using the ForeseeHome device. The test, which takes about 3 minutes, per eye is simple to perform, and results are automatically transferred to the Notal Vision monitoring center and are available to the patient’s eye doctor through a secure website. When a statistically significant change is detected on a patient’s test, Notal Vision sends a prompt to the doctor to schedule a follow up appointment.
About Notal Vision, Inc.
Notal Vision was founded by two ophthalmologists, and is committed to providing retina specialists with innovative, home-based, technology solutions that support visual health in patients with AMD. The company's ForeseeHome® device is the first FDA-cleared home telemonitoring device that detects and characterizes visual distortion in AMD patients as an aid to monitoring progression to choroidal neovascularization.
